Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry
The aim of this prospective cohort study was to assess current antianemic treatment of cancer patients in German routine practice, including diagnostics, treatments, and quality of life (QoL). 88 study sites recruited 1018 patients at the start of antianemic treatment with hemoglobin (Hb) levels <...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Anemia |
| Online Access: | http://dx.doi.org/10.1155/2016/8057650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565528409931776 |
|---|---|
| author | Tilman Steinmetz Jan Schröder Margarete Plath Hartmut Link Michèle Vogt Melanie Frank Norbert Marschner |
| author_facet | Tilman Steinmetz Jan Schröder Margarete Plath Hartmut Link Michèle Vogt Melanie Frank Norbert Marschner |
| author_sort | Tilman Steinmetz |
| collection | DOAJ |
| description | The aim of this prospective cohort study was to assess current antianemic treatment of cancer patients in German routine practice, including diagnostics, treatments, and quality of life (QoL). 88 study sites recruited 1018 patients at the start of antianemic treatment with hemoglobin (Hb) levels <11 g/dL (females) or <12 g/dL (males). Patients were followed up for 12 weeks. 63% of the patients had inoperable solid tumors, 22% operable solid tumors, and 15% hematological malignancies. Over 85% received chemotherapy. Median age was 67 years; 48% were male. Red blood cell transfusions (RBCTx) were given to 59% of all patients and to 55% of the patients with Hb ≥8 g/dL on day 1 of the observation period (day 1 treatment). Erythropoiesis-stimulating agents (ESAs) were the second most frequently applied day 1 treatment (20%), followed by intravenous (IV) iron (15%) and ESA + IV iron (6%). Only about a third of patients were tested for blood serum iron parameters at the start of treatment. Overall, more than half of the patients had long-term responses to antianemic therapy. Our data suggest that in routine practice diagnostics for treatable causes of anemia are underused. A high proportion of cancer patients receive RBCTx. It should be discussed whether thorough diagnostics and earlier intervention could decrease the need for RBCTx. This trial is registered with NCT01795690. |
| format | Article |
| id | doaj-art-b9d0c1f603694420bf2e9e4e04c8fcbe |
| institution | Kabale University |
| issn | 2090-1267 2090-1275 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anemia |
| spelling | doaj-art-b9d0c1f603694420bf2e9e4e04c8fcbe2025-02-03T01:07:26ZengWileyAnemia2090-12672090-12752016-01-01201610.1155/2016/80576508057650Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia RegistryTilman Steinmetz0Jan Schröder1Margarete Plath2Hartmut Link3Michèle Vogt4Melanie Frank5Norbert Marschner6Outpatient Clinic for Hematology and Oncology, Sachsenring 69, 50677 Cologne, GermanyOutpatient Clinic for Oncology, Kettwiger Strasse 62, 45468 Mülheim an der Ruhr, GermanyOutpatient Clinic for Oncology, Prinzregentenstrasse 1, 86150 Augsburg, GermanyDepartment for Internal Medicine I, Westpfalz-Klinikum, Hellmut-Hartert-Strasse 1, 67655 Kaiserslautern, GermanyiOMEDICO, Hanferstrasse 28, 79108 Freiburg, GermanyiOMEDICO, Hanferstrasse 28, 79108 Freiburg, GermanyOutpatient Clinic for Interdisciplinary Oncology and Hematology, Wirthstrasse 11c, 79110 Freiburg, GermanyThe aim of this prospective cohort study was to assess current antianemic treatment of cancer patients in German routine practice, including diagnostics, treatments, and quality of life (QoL). 88 study sites recruited 1018 patients at the start of antianemic treatment with hemoglobin (Hb) levels <11 g/dL (females) or <12 g/dL (males). Patients were followed up for 12 weeks. 63% of the patients had inoperable solid tumors, 22% operable solid tumors, and 15% hematological malignancies. Over 85% received chemotherapy. Median age was 67 years; 48% were male. Red blood cell transfusions (RBCTx) were given to 59% of all patients and to 55% of the patients with Hb ≥8 g/dL on day 1 of the observation period (day 1 treatment). Erythropoiesis-stimulating agents (ESAs) were the second most frequently applied day 1 treatment (20%), followed by intravenous (IV) iron (15%) and ESA + IV iron (6%). Only about a third of patients were tested for blood serum iron parameters at the start of treatment. Overall, more than half of the patients had long-term responses to antianemic therapy. Our data suggest that in routine practice diagnostics for treatable causes of anemia are underused. A high proportion of cancer patients receive RBCTx. It should be discussed whether thorough diagnostics and earlier intervention could decrease the need for RBCTx. This trial is registered with NCT01795690.http://dx.doi.org/10.1155/2016/8057650 |
| spellingShingle | Tilman Steinmetz Jan Schröder Margarete Plath Hartmut Link Michèle Vogt Melanie Frank Norbert Marschner Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry Anemia |
| title | Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry |
| title_full | Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry |
| title_fullStr | Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry |
| title_full_unstemmed | Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry |
| title_short | Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry |
| title_sort | antianemic treatment of cancer patients in german routine practice data from a prospective cohort study the tumor anemia registry |
| url | http://dx.doi.org/10.1155/2016/8057650 |
| work_keys_str_mv | AT tilmansteinmetz antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT janschroder antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT margareteplath antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT hartmutlink antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT michelevogt antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT melaniefrank antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry AT norbertmarschner antianemictreatmentofcancerpatientsingermanroutinepracticedatafromaprospectivecohortstudythetumoranemiaregistry |